Background Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection. We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia.
Introduction
B-cell receptor signalling in both normal and malignant B-cells provides a strong proliferative and survival signal to the cell. 1, 2 Interfering with such signalling is therefore a logical approach to treatment of B-cell malignancies. 3, 4 Ibrutinib (PCI-32765, Pharmacyclics, Sunnyvale, CA, USA) is a covalent inhibitor of Bruton tyrosine kinase (BTK), an important enzyme in the B-cell receptor signalling cascade. 5 Patients who have inherited mutations in BTK have X-linked agamma globulinaemia (also known as Bruton agamma globulinaemia), a disease associated with diminished B-cell numbers, decreased serum immunoglobulin concentrations, and increased susceptibility to infections.
Ibrutinib forms a covalent bond with the BTK cysteine-481 residue, potently inhibiting enzyme activity inhibition even at nanomolar concentrations. 6 Several preclinical studies have shown the proapoptotic, antiproliferative, and stromal inhibitory properties of this drug in primary chronic lymphocytic leukaemia cells. [7] [8] [9] Ibrutinib is orally bioavailable, and no maximum tolerated dose was reached when it was given once daily at doses of 2·5-12·5 mg/kg continuously until disease progression in a phase 1 trial of 56 patients with various relapsed or refractory B-cell cancers. 10 Of the 50 assessable patients in the study, 60% achieved an objective response, with a median progression-free survival of 13·6 months. 10 Phase 2 data for patients with relapsed or refractory chronic lymphocytic leukaemia treated with ibrutinib showed a high proportion of patients achieving an objective response and durable remissions, with an estimated progression-free survival of 75% and overall survival of 83% during the study of a heavily pretreated population of patients (patients had a median of four previous nonibrutinib regimens).
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Chemoimmunotherapy is the standard front-line approach for patients younger than 65 years with chronic lymphocytic leukaemia, with the combination of fl udarabine, cyclophosphamide, and rituximab used most commonly. [12] [13] [14] However, treatment with chemoimmuno therapy is associated with high rates of myelosuppression and infection; such complications are more frequent and more severe in patients older than 65 years because of reduced marrow reserve, and presence of comor bidities. [15] [16] [17] The German Chronic Lymphocytic Leukaemia Study Group reported the fi rst randomised study 18 of chlorambucil versus single-agent fl udarabine in a cohort of previously untreated patients who were older than 65 years and had chronic lymphocytic leukaemia. Although a greater proportion of patients who were treated with fl udarabine achieved an objective response than those treated with chlorambucil, additional toxicity was noted with fl udarabine and fl udarabine did not lead to a benefi t in overall survival. 18 Analysis of US Intergroup data similarly concluded that chlorambucil might be an acceptable treat ment for elderly patients (aged >65 years) with chronic lymphocytic leukaemia, and suggested that the addition of immuno therapy with the anti-CD20 monoclonal antibody rituximab might have a benefi t irrespective of age. 19 Addition of a CD20 monoclonal antibody to chlorambucil treatment in elderly patients with chronic lymphocytic leukaemia has been previously shown to be benefi cial (median age of the study population 73 years), 20 with early assessment of median progression-free survival for the combination reported as slightly less than 2 years, as compared with 10·9 months with chlorambucil alone.
Eff ective agents with few toxic eff ects are needed for elderly patients. In view of the excellent tolerability and safety profi le of ibrutinib, and the high proportion of relapsed patients who achieved an objective response, we aimed to assess the safety and effi cacy of ibrutinib in previously untreated patients aged 65 years and older with chronic lymphocytic leukaemia or small lymphocytic lymphoma. In addition, the study sought to examine the eff ect of genomic features on response to ibrutinib.
Methods

Study design and participants
In our phase 1b/2, open-label, multicentre study, we enrolled participants at seven clinical sites in the USA (appendix). Study sites were selected on the basis of their participation in the fi rst clinical study, 10 with selection of additional sites based on a sponsor feasibility assessment. Eligible participants were previously untreated, were aged at least 65 years, and had a diagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma as defi ned by the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) 21 and WHO 22 classifi cations, a current requirement for treatment according to US National Cancer Institute or IWCLL guidelines, Eastern Cooperative Oncology Group (ECOG) performance statuses of 2 or lower, adequate organ function (including creatinine 1·5 times the upper limit of normal or lower, and alanine aminotransferase 2·5 times the upper limit of normal or lower), and an absence of active infection. Exclusion criteria included any cancer restricting expected survival to less than 2 years, gastrointestinal disease that could inhibit absorption of ibrutinib, and medicines associated with torsades de pointes.
An institutional review board approved the protocol at the respective sites, and the study was conducted according to the principles of the Declaration of Helsinki, the International Conference on Harmonisation, and the Guidelines for Good Clinical Practice. All patients provided written informed consent.
Procedures
Eligible participants received 28 day cycles of once-daily ibrutinib 420 mg (three 140 mg capsules) or once-daily ibrutinib 840 mg (six 140 mg capsules). Patients were assigned sequentially by enrolment. Although we initially planned to assess two fi xed doses of ibrutinib, we closed the 840 mg per day cohort before full accrual after comparable activity of the doses was shown elsewhere in relapsed or refractory patients with chronic lymphocytic leukaemia. 11 Ibrutinib treatment was delayed in the event of any uncontrolled, potentially drug-related grade 3 or worse toxicity. Doses could also be held in the event of grade 4 neutropenia occurring for more than 7 days, grade 3 or worse drop in platelet count, and grade 3 or worse diarrhoea, nausea, or vomiting. Ibrutinib treatment could be resumed when the toxicity resolved, and if toxicity re-occurred a dose reduction was mandated. Extensive dose holds (longer than 28 days) for toxicity resulted in permanent discontinuation of the study drug. Ibrutinib was to be given continuously, until disease progression or toxic eff ects led to discontinuation.
The primary endpoint was the safety of the fi xed-dose regimen assessed by the frequency and severity of adverse events. The study was designed to terminate when the safety endpoints were validated. Patients were followed up for at least 12 cycles in the study, and then could continue ibrutinib treatment in a long-term extension study. Patients were monitored by history, physical examination, and peripheral blood drawn every week for the fi rst month, every other week for the second month, and monthly thereafter. Adverse events were graded according to the Common Toxicity Criteria of the National Cancer Institute, Version 4.0. We graded haematological toxicities according to IWCLL 2008 criteria. 21 Secondary endpoints were the proportion of patients achieving an overall response, progression-free survival, long-term tolerability, and pharmacodynamics. We did a response assessment, including a CT radiological examination at the end of cycles 2, 5, 8, 12, 15, and 24. We took a bone marrow biopsy sample to confi rm complete responses. 21 All patients had baseline assessments of blood count; however, baseline bone marrow biopsy was not required or collected at study entry. We assessed response in patients with chronic lymphocytic leukaemia on the basis of IWCLL guidelines, 21 with the exception that lymphocytosis was not a sole criterion for progression (as per Hallek and colleagues 23 ). A partial response in all other parameters in the setting of persistent lymphocytosis was characterised as a partial response with lymphocytosis. 24 Response in patients with small lymphocytic lymphoma was assessed on the basis of the International Working Group for non-Hodgkin 25 We assessed haematological improvement in the subset of patients with cytopenia (haemoglobin ≤110 g/L, platelet counts of ≤100 × 10⁹ platelets per L or absolute neutrophil counts ≤1·5 × 10⁹ cells per L) at baseline. Haematological improvement was defi ned as haemoglobin of more than 110 g/L or an increase of at least 50% from baseline, platelet counts of more than 100 × 10⁹ platelets per L or an increase of at least 50% from baseline, absolute neutrophil counts of more than 1·5 × 10⁹ cells per L or an increase of at least 50% from baseline. We defi ned sustained haematological improvement as duration of response lasting for at least 56 days (two cycles) without transfusions or provision of growth factors. Exploratory endpoints included identifi cation of putative biomarkers of response, and overall survival. We required all patients to have an IWCLL indication for therapy as part of eligibility, but the exact criteria for which they met this indication were not collected.
We assessed ZAP-70 methylation as previously described; 26 ZAP-70 was regarded as methylated at CpG3 if scores were at least 15%. We assessed IgG, IgA, and IgM levels for patients who did not receive intravenous immunoglobulins as concomitant therapy during ibrutinib treatment. We assessed levels at baseline and at cycles 3, 6, and 12. Testing for interphase cytogenetics, immunoglobulin gene (IgHV) mutational analysis, and β2 microglobulin concentrations was done at baseline by a central laboratory (Ohio State University central laboratory, Columbus, OH, USA).
For pharmacodynamic analyses, we assessed the level of BTK occupancy in blood mononuclear cells following treatment at both dose levels. A cell-permeable, fl uorescently tagged derivative of ibrutinib, PCI-33380, was used to visualise BTK binding before treatment and at 4 h and 24 h after treatment. 6 
Statistical analysis
A sample size of 12-24 patients per group for the two fi xed-dose daily regimens of ibrutinib was considered to defi ne the preliminary safety profi le of ibrutinib, without power considerations. No hypothesis testing was planned in this study. We planned to enrol 36 patients: 24 in the 420 mg cohort and 12 in the 840 mg cohort. The 840 mg cohort, however, closed before full accrual after comparable activity of the doses was shown elsewhere in relapsed or refractory patients with chronic lymphocytic leukaemia. 11 We report all subgroup analyses undertaken.
We report descriptive statistics. Because few patients received an ibrutinib dose of 840 mg and the results for the two dose cohorts were similar, we pooled data for all patients. We did the analyses for all patients who received any dose of study drug. We calculated the proportion of patients achieving an objective response using an exact binomial 95% CI. We used the Kaplan-Meier method for time-to-event analysis (curves and corresponding quartiles). Patients were censored for progression-free survival at the last clinical assessment before receipt of new anticancer therapy, or after loss to follow-up, whichever occurred fi rst. Patients were censored for overall survival at the last known alive date. No imputation was done for missing data. Exploratory analysis to identify characteristics associated with response in each subgroup was compared by patients achieving a response with an exact binomial 95% CI, which is only used as indicative. We did not adjust for multiplicity. This analysis shows the fi nal data from our study, extracted on Feb 27, 2013. All statistical analyses were done with SAS version 9.3 under the Windows server 2008 R2 enterprise service pack 1 on a validated and secured computing system. This study is registered with ClinicalTrials.gov, number NCT01105247.
Role of the funding source
This study was sponsored by Pharmacyclics. Clinical investigators were responsible for design of the study protocol and analysis plan together with Pharmacyclics. The investigators and their respective research teams collected all of the data, and Pharmacyclics confi rmed the accuracy of the data and compiled the data for summation and analysis. Investigators had full access to the data and analyses for compilation of this report. SO'B wrote the fi rst draft of the manuscript; all authors carefully reviewed the manuscript and approved the fi nal version. The corresponding author had full access to all of the data and had fi nal responsibility to submit for publication.
Results
Between May 20, 2010, and Dec 18, 2012, we enrolled 29 patients with symptomatic chronic lymphocytic leukaemia and two patients with symptomatic small (table 1) . At the time of analysis, median follow-up for all patients was 22·1 months (IQR 18·4-23·2). 27 patients were treated with ibrutinib 420 mg and four were treated with ibrutinib 840 mg. Median treatment duration was 21·0 months (14·8-22·6). The relative dose intensity (percentage of expected dose received) was 98·9% (range 49·9-100·0; IQR 96·9-99·9). Only one patient required dose modifi cation for nausea (grade 1 nausea from day 30 to day 322, which was regarded as possibly related to treatment), and was maintained on a lower dose of 280 mg after day 176.
Two patients discontinued treatment because of adverse events, including grade 3 fatigue in one patient and grade 2 viral infection in a second patient. Two patients withdrew consent (one patient withdrew consent to start a new treatment option because of an insuffi cient improvement; the second patient withdrew consent to continue in this clinical trial and further data were not provided). Only one patient progressed; the patient, who had del(17p13.1), achieved an initial response after 3·7 months of ibrutinib therapy, and later developed Richter's transformation at 9·6 months. After discontinuation of ibrutinib, this patient received salvage therapy with oxaliplatin, fl udarabine, cytarabine, and rituximab, and died of progressive disease 113 days after the last dose of ibrutinib; this patient was the only participant who died on the study. 26 (84%) of 31 patients continued treatment in the long-term extension study. Nine (29%) of 31 patients required ibrutinib treatment to be held due to grade 3 or greater toxicity.
22 (71%, 95% CI 52·0-85·8) of 31 patients achieved an objective response (defi ned as complete and partial responses, table 2, fi gure 1), with four (13%) achieving a complete response. Four patients (13%) had a partial response with lymphocytosis, and three patients (10%) had stable disease; median follow-up for these seven patients was 20·3 months (IQR 14·7-22·8), as compared with 22·1 months (20·3-23·2) for the 22 patients who achieved partial or complete response. Of the 22 patients who achieved a complete or partial response, the initial responses were ten partial responses with lymphocytosis, and 12 true partial responses. For the ten patients who initially responded with partial response with lymphocytosis, the median time to true partial response or complete response was 7·3 months (IQR 4·6-7·4).
We did subgroup analyses for proportion of patients achieving an objective response for various predetermined prognostic variables (fi gure 2). In every comparison, the 95% CI overlapped, so none of these diff erences was regarded as signifi cant. Patients with unmutated IgHV might have been predisposed to achieve a partial response or complete response, due to more rapid resolution of lymphocytosis. However, if partial response with lymphocytosis is included, we noted no apparent diff erence in the proportion of patients achieving an objective response based on mutational status (data not shown), which supports previous fi ndings for relapsed patients receiving ibrutinib. 11 Baseline absolute lymphocyte count in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma was high, with a median of 41 × 10⁹ cells per L (IQR 25·8 × 10⁹-67·9 × 10⁹). Ibrutinib led to lymphocytosis in 17 (55%) of 31 patients, peaking at a median of 1·1 weeks (IQR 1·1-3·9) and then slowly declining (fi gure 3). The lymphocytosis occurred together with a notable reduction in lymph node size that was sustained over the course of treatment (fi gure 3). Most patients normalised (absolute lymphocyte count <4 × 10⁹ cells per L) or achieved greater than 50% reduction from baseline in their absolute lymphocyte count during follow-up. Of 13 patients who achieved a partial response with lymphocytosis at some time during their treatment, two ultimately achieved a complete response and seven achieved a partial response with resolution of lymphocytosis.
Median time to initial response was 1·9 months (IQR 1·8-4·6); median time to best response was 5·9 months (1·9-8·3) and median time to complete response was 12·4 months (9·1-14·7). For all 31 patients at 24 months, the Kaplan-Meier estimate of progressionfree survival was 96·3% (95% CI 76·5-99·5) and overall survival was 96·6% (77·9-99·5; fi gure 4). There was no diff erence by dose, although numbers were small (appendix). Median progression-free survival was not reached, with only one patient progressing during follow-up, providing a 24 month progressionfree survival of 96·3% (95% CI 76·5-99·5). Pharmacodynamic assessments showed that the median BTK occupancy of cycle 1 was more than 90% for both treatment groups, before or after drug administration on days 1 and 8 (fi gure 5). Of the four patients who had less than 90% BTK occupancy (in one of whom BTK occupancy was less than 90% at two timepoints), two achieved partial responses, and two achieved complete responses. All four patients remained progression free and continued on ibrutinib until study closure, and continued therapy on the long-term extension study.
The most common adverse event was diarrhoea, which was reported for most patients (table 3) . This adverse event was often self-limited and resolved without discontinuation of the drug. No episodes of grade 4 diarrhoea occurred, and no treatment discontinuation resulted from this adverse event. Other adverse events that were commonly reported in patients included nausea (mainly grade 1, with a maximum grade of 2), up to grade 3 fatigue, and hypertension (table 3) . Three patients had grade 3 infections, but no higher grade infections were reported. One patient had grade 3 neutropenia and one had grade 4 thrombocytopenia; no anaemia of grade 3 or greater was reported. No patients died from causes related to treatment or, within 30 days of last treatment of study drug. We noted no diff erences in the safety profi les of patients who received once-daily ibrutinib 420 mg and those who received 840 mg (data not shown). However, because of the imbalance in patients (27 received ibrutinib 420 mg vs four patients received ibrutinib 840 mg), a conclusive statement cannot be made about these safety profi les. Notable improvements in baseline cytopenias were frequent (fi gure 6). 12 (39%) of 31 patients started treatment with a platelet count of fewer than 100 × 10⁹ platelets per L and seven (58%) of these 12 patients had sustained improvement to counts of more than 100 × 10⁹ platelets per L. 11 (35%) of 31 patients started treatment with haemoglobin concentrations of less than 110 g/L, and seven (64%) of these 11 patients had sustained improvement in the haemoglobin.
Median serum IgA increased between baseline measure ment and measurement at 12 cycles; no changes were seen in serum IgM and serum IgG concentrations over time (table 4; fi gure 7).
Discussion
Our study suggests that orally administered ibrutinib, a potent, covalent inhibitor of BTK, is well tolerated and eff ective in a previously untreated population of elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Our elderly and treatment-naive patient population was selected to receive ibrutinib investigational therapy based on previous data from relapsed patients with chronic lymphocytic leukaemia who were treated with ibrutinib; the data showed that ibrutinib showed good tolerability and led to a high proportion of patients achieving an objective response (panel).
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Although chemo immunotherapy is the standard of care for fi t patients with chronic lymphocytic leukaemia, equivalent treatment in older patients or in those with signifi cant comorbidities is often not well tolerated. 15, 16 Ibrutinib was well tolerated in our study, although mild diarrhoea was a common, albeit self-limiting, adverse event early in the treatment course. Because the drug is minimally myelosuppressive in patients with chronic lymphocytic leukaemia, haematological toxicity was rare and infections were uncommon, despite only four patients receiving replacement intravenous immunoglobulins while on study. This fi nding is contrary to typical sideeff ects noted with chemoimmunotherapy for this elderly population of previously untreated patients, in whom myelosuppression is common, and often associated with infections. Future studies looking at subsets of immune cells in patients treated with ibrutinib will be informative about the eff ect of ibrutinib on other normal lymphocytes, including T cells and natural killer cells, as ibrutinib also inhibits interleukin-inducible kinase (which has immune-modulating potential). 35 A systematic assessment of constitutional or B symptoms in patients receiving ibrutinib would be a worthwhile analysis, but was not done in the context of this study.
Time to initial response (complete response, partial response, or partial response with lymphocytosis) and time to best response (complete or partial response) were based on the 22 patients who achieved complete or partial response as assessed by IWCLL guidelines. The diff erence between initial and best response is due to many patients achieving an initial response at about 2 months, and then achieving a better response later (at about 6 months). The four patients who achieved complete response took a median of around 12 months to achieve it: the longest of all response times. 
Participants with data
Overall 31 22 (71%) of 31 patients achieved an objective response, with an additional four (13%) achieving a partial response with lymphocytosis. Not only did a high proportion of patients achieve an objective response in this study, but the times to these responses were rapid (median time to response 1·9 months) and durable during the conduct of the study (median duration of response not estimable). We noted resolution of lymphocytosis and subsequent partial or complete response in nine (69%) of 13 of these patients during follow-up on this study. Four patients achieved partial response with lymphocytosis, and did not convert to a true partial or complete response during follow-up on this study; these patients continue on ibrutinib therapy in the setting of a long-term extension study. Although only four (13%) patients achieved a complete response, this fi nding might be partly explained by the lack of requirement for periodic bone marrow biopsies apart from when confi rming complete response. This requirement was inconsistently followed by the investigators. As such, two patients who appeared in clinical complete remission, but who did not have a bone marrow biopsy to assess complete response, were classifi ed as only achieving a partial response.
As previously reported in a relapsed population of patients with chronic lymphocytic leukaemia who were treated with ibrutinib, responses did not vary with the presence or absence of high-risk prognostic factors in our study. 11 However, the frequency of patients with the high-risk genetic abnormalities del(17p13.1) or del(11q22.3), or with increased β2-microglobulin was relatively low in this study. Large future studies in highrisk populations will be needed to defi nitively assess the eff ect of ibrutinib on these high-risk subgroups.
Median progression-free survival was not reached, with only one patient progressing during follow-up. Of the four patients who were censored before 6 months for progression-free survival, two were also censored for overall survival before 6 months, and the other two were censored for overall survival at 25·3 months and 28·9 months, respectively. The diff erences in censoring Cycle 12  Cycle 6  Cycle 3  Baseline  Cycle 12  Cycle 6  Cycle 3  Baseline   n=19  n=23  n=22  n=26  n=16  n=20  n=18  n=23  n=18  n=22  n=21  n=25 times were due to the diff erent censoring rules we used for progression-free survival and overall survival.
Chlorambucil is often regarded as a standard treatment option for elderly patients, with most published trials suggesting a median progression-free survival of 8-18 months. 17, 27, 28 Combination treatments with a chlorambucil backbone and an anti-CD20 monoclonal antibody (eg, rituximab, ofatumumab, or obinutuzumab) have been reported to achieve longer progression-free survival than chlorambucil alone, with reported median progression-free survival of 15·7-24·0 months with the chemoimmunotherapy combin ations. 20, 29, 30 Recently, lenalidomide has been used as initial therapy in patients older than 65 years with chronic lymphocytic leukaemia, 31 with 65% of patients achieving an objective response (including 10% achieving a complete response). 83% of patients in the study had at least one episode of grade 3-4 neutropenia and the estimated 2 year progression-free survival was 60%.
An unresolved question is whether improvements in outcome are associated with rapid achievement of responses. The low degree of myelosuppression reported with ibrutinib in patients with chronic lymphocytic leukaemia, and the low levels of non-haematological toxicities, make this a useful agent to use in combination with other therapies, especially other non-cytotoxic therapies, including B-cell-depleting monoclonal antibodies such as rituximab. This combination has led to relapsed patients with chronic lymphocytic leukaemia achieving a high frequency of objective response (17 [85%] of 20 patients assessable for early response assessment at 3 months) together with an early resolution of lymphocytosis compared with single-agent ibrutinib. 32 Additional ibrutinib com binations, including with other targeted agents such as PI3K inhibitors, agents that target anti-apoptotic proteins, and cyclin-dependent kinase inhibitors, could be explored. However, combination with other drugs might lead to additional toxicities, potentially an important factor to consider in an elderly population of patients. Furthermore, the long-term benefi t of such combinations in view of the durability of remission reported to date with ibrutinib is unknown.
The elderly population of previously untreated patients assessed in this trial had several comorbidities. Comorbidites are common in elderly individuals, and are increasingly severe and frequent as people age. A trial 16 of fl udarabine and cyclophosphamide alone or with rituximab enrolled patients older than 70 years (but not >81 years); notably, all participants had to have a creatinine clearance of more than 70 mL/min and a comorbidity score of less than 6. However, only 8% of all patients older than 65 years who attended the MD Anderson Leukemia Clinic (Houston, TX, USA) in 1 month met such criteria (O'Brien S; unpublished data). Treatment of all patients older than 70 years with fl udarabine-based therapy showed that such patients had increased toxicity compared with younger patients and were often unable to complete the planned six cycles of therapy, whereas in the present study the median treatment duration for the 23 patients 70 years and older was 21·7 months (IQR 14·8-23·1) with only two of these patients requiring treatment discontinuation for an adverse event. 33, 34 In conclusion, our data support continued assessment of ibrutinib in this population of patients. Two phase 3 trials of ibrutinib in this population examining progression-free survival are ongoing or planned: RESONATE-2, comparing effi cacy with chlorambucil or ibrutinib (NCT01722487), and NCT01886872 examining bendamustine-rituximab versus ibrutinib-rituximab versus ibrutinib.
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